Visualizable, AKR1C3-Activated Small-Molecule Antitumor Drug Conjugates with Ultra-Low Systemic Toxicity

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Developing targeted antitumor agents with minimal systemic toxicity is a significant challenge in cancer therapy.
• Exatecan, a potent camptothecin derivative, has limitations in clinical use due to toxicity and efficacy issues.
• Targeting tumor-specific enzymes like Aldo-keto Reductase Family 1 Member C3 (AKR1C3) offers a strategy for selective drug activation.

Purpose of the Study:

• To design and synthesize novel Exatecan conjugates (EP-1 and EP-2) that are responsive to the tumor-enriched enzyme AKR1C3.
• To evaluate the targeted drug release, cytotoxicity, and systemic toxicity of these novel conjugates.
• To establish a biomarker-driven approach for developing safer and more effective antitumor therapies.

Main Methods:

• Design and synthesis of two AKR1C3-responsive Exatecan conjugates (EP-1, EP-2) incorporating a fluorescence-quenched module.
• In vitro cytotoxicity assays in cancer cells with varying AKR1C3 expression levels.
• In vivo studies using a mouse model and zebrafish imaging to assess drug release and efficacy.

Main Results:

• EP-1 and EP-2 demonstrated potent cytotoxicity in AKR1C3-high cancer cells, comparable to Exatecan.
• The conjugates exhibited markedly reduced toxicity in AKR1C3-low and normal cells, indicating targeted activation.
• EP-2 showed potent antitumor efficacy with significantly reduced systemic toxicity in a mouse model, surpassing Exatecan's safety profile.

Conclusions:

• The novel AKR1C3-responsive Exatecan conjugates, particularly EP-2, are promising candidates for selective and safe tumor therapy.
• This study presents a new paradigm for biomarker-driven antitumor drug design, enabling targeted drug delivery and activation.
• The developed conjugates offer a potential solution to overcome limitations of existing chemotherapies and improve patient outcomes.